ArticleEClinicalMedicine2024

Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.

Puyuan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.